Figure 1
Figure 1. Increased expression of p15Ink4b mRNA in cDCs. (A) FACS plots depicting the gating strategy for FACS sorting of mouse FACS-sorted c-Kit+ cells from lineage-negative enriched BM progenitors (left) and CD11c+/CD11b+ splenic cDCs from enriched splenic DCs (right). DCs were enriched using a negative-enrichment cocktail containing biotinylated Abs against murine CD2, CD90.2, CD19, Ly-6G, and TER-119. (C) CD11c+CD11b+ BM-DCs from the GM-CSF and IL-4 BM cultures. (B,D,G) Real-time qPCR analysis of p15Ink4b mRNA levels of the sorted populations of cells. (E) Human CD34+ progenitors and CD34-derived CD1c+CD11b+ cDCs. Cells were harvested at the indicated time points. (F) Bright-field images of human CD34+ progenitors (left) and CD34-derived DCs on day 5 of culture (right). Scale bar represents 20 μm. Images were collected using an Olympus iX51 inverted microscope, a EXi Aqua Camera (QImaging), and the acquisition software IPlab Version 4.08 (BD Biosciences), and were processed in Adobe Photoshop Version 5.0.

Increased expression of p15Ink4b mRNA in cDCs. (A) FACS plots depicting the gating strategy for FACS sorting of mouse FACS-sorted c-Kit+ cells from lineage-negative enriched BM progenitors (left) and CD11c+/CD11b+ splenic cDCs from enriched splenic DCs (right). DCs were enriched using a negative-enrichment cocktail containing biotinylated Abs against murine CD2, CD90.2, CD19, Ly-6G, and TER-119. (C) CD11c+CD11b+ BM-DCs from the GM-CSF and IL-4 BM cultures. (B,D,G) Real-time qPCR analysis of p15Ink4b mRNA levels of the sorted populations of cells. (E) Human CD34+ progenitors and CD34-derived CD1c+CD11b+ cDCs. Cells were harvested at the indicated time points. (F) Bright-field images of human CD34+ progenitors (left) and CD34-derived DCs on day 5 of culture (right). Scale bar represents 20 μm. Images were collected using an Olympus iX51 inverted microscope, a EXi Aqua Camera (QImaging), and the acquisition software IPlab Version 4.08 (BD Biosciences), and were processed in Adobe Photoshop Version 5.0.

Close Modal

or Create an Account

Close Modal
Close Modal